C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
24 11 2020
24 11 2020
Historique:
received:
11
09
2020
accepted:
21
10
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed the natural history of relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphoma. Based on these results, CD19 CAR T cells have since been tested in largely incurable lymphomas, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma, with promising early results that raise the question of whether this cellular immunotherapy could have curative potential and change the natural history of these diseases. This article reviews these results and this hypothesis.
Identifiants
pubmed: 33232481
pii: S2473-9529(20)31984-4
doi: 10.1182/bloodadvances.2020003391
pmc: PMC7686908
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Antigen, T-Cell
0
Tolnaftate
06KB629TKV
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5858-5862Informations de copyright
© 2020 by The American Society of Hematology.
Références
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72
pubmed: 25730880
J Exp Med. 1988 Feb 1;167(2):582-97
pubmed: 3126254
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
Stem Cell Res. 2010 Nov;5(3):212-25
pubmed: 20851072
Blood. 2016 Mar 24;127(12):1559-63
pubmed: 26764355
Leukemia. 2017 Jan;31(1):246-248
pubmed: 27677739
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Sci Signal. 2020 Mar 31;13(625):
pubmed: 32234960
N Engl J Med. 2018 Mar 15;378(11):1065
pubmed: 29539277
J Cell Mol Med. 2010 Jun;14(6B):1532-45
pubmed: 19656242
Blood. 2013 Oct 10;122(15):2539-49
pubmed: 23886836
Nat Med. 2020 Oct;26(10):1569-1575
pubmed: 33020647
Blood. 2016 Mar 3;127(9):1117-27
pubmed: 26813675
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32484797
J Clin Invest. 2020 Jun 1;130(6):3087-3097
pubmed: 32069268
Blood. 2019 Aug 15;134(7):636-640
pubmed: 31648294
Blood. 2018 Feb 1;131(5):587-588
pubmed: 29437609
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
pubmed: 19211796
Oncoimmunology. 2020 Jul 3;9(1):1785608
pubmed: 32923149
Clin Cancer Res. 2016 Jun 1;22(11):2684-96
pubmed: 26819453
Blood. 2020 Oct 1;136(14):1632-1644
pubmed: 32556247
J Clin Invest. 2017 Aug 1;127(8):3052-3064
pubmed: 28714866
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Blood. 1998 Jun 15;91(12):4708-14
pubmed: 9616169
Sci Rep. 2017 Sep 5;7(1):10541
pubmed: 28874817
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Nat Commun. 2019 May 7;10(1):2087
pubmed: 31064990
Nat Commun. 2018 Aug 3;9(1):3049
pubmed: 30076299
Mol Ther. 2020 Dec 2;28(12):2577-2592
pubmed: 32755564
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
JCI Insight. 2019 Apr 2;5:
pubmed: 30938714